{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:55:21Z","timestamp":1794592521939,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"crossref","award":["R01NS034239-25"],"award-info":[{"award-number":["R01NS034239-25"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Nebraska Foundation, Private Donations"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer\u2019s disease. The safety, tolerability, and mechanisms of action in Parkinson\u2019s disease (PD) during extended use has not been evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>As a primary goal, safety and tolerability was assessed in five PD patients treated with sargramostim (Leukine<jats:sup>\u00ae<\/jats:sup>, granulocyte\u2013macrophage colony-stimulating factor) for 33\u00a0months. Secondary goals included numbers of CD4<jats:sup>+<\/jats:sup>T cells and monocytes and motor functions. Hematologic, metabolic, immune, and neurological evaluations were assessed during a 5-day on, 2-day off therapeutic regimen given at 3\u00a0\u03bcg\/kg. After 2 years, drug use was discontinued for 3 months. This was then followed by an additional 6 months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sargramostim-associated adverse events included injection-site reactions, elevated total white cell counts, and bone pain. On drug, blood analyses and metabolic panels revealed no untoward side effects linked to long-term treatment. Unified Parkinson\u2019s Disease Rating Scale scores remained stable throughout the study while regulatory T cell number and function were increased. In the initial 6\u00a0months of treatment, transcriptomic and proteomic monocyte tests demonstrated autophagy and sirtuin signaling. This finding paralleled anti-inflammatory and antioxidant activities within both the adaptive and innate immune profile arms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taken together, the data affirmed long-term safety as well as immune and anti-inflammatory responses reflecting clinical stability in PD under the sargramostim treatment. Confirmation in larger patient populations is planned in a future phase II evaluation.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov: NCT03790670, Date of Registration: 01\/02\/2019, URL:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03790670?cond=leukine+parkinson%27s&amp;draw=2&amp;rank=2\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03790670?cond=leukine+parkinson%27s&amp;draw=2&amp;rank=2<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40035-023-00361-1","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T06:02:08Z","timestamp":1684735328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["An open-label multiyear study of sargramostim-treated Parkinson\u2019s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers"],"prefix":"10.1186","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03790670","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katherine E.","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai M.","family":"Abdelmoaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Namminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaman","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Obaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lee","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"7","key":"361_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT. Parkinson\u2019s disease and parkinsonism. Am J Med. 2019;132(7):802\u20137.","journal-title":"Am J Med"},{"issue":"2","key":"361_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","volume":"103","author":"SG Reich","year":"2019","unstructured":"Reich SG, Savitt JM. Parkinson\u2019s disease. Med Clin North Am. 2019;103(2):337\u201350.","journal-title":"Med Clin North Am"},{"issue":"2","key":"361_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14737175.2019.1561285","volume":"19","author":"DLM Radder","year":"2019","unstructured":"Radder DLM, de Vries NM, Riksen NP, Diamond SJ, Gross D, Gold DR, et al. Multidisciplinary care for people with Parkinson\u2019s disease: the new kids on the block! Expert Rev Neurother. 2019;19(2):145\u201357.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"361_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.27720","volume":"34","author":"C Marras","year":"2019","unstructured":"Marras C, Canning CG, Goldman SM. Environment, lifestyle, and Parkinson\u2019s disease: implications for prevention in the next decade. Mov Disord. 2019;34(6):801\u201311.","journal-title":"Mov Disord"},{"issue":"7","key":"361_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, Aer IR, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells. 2020;9(7):1687.","journal-title":"Cells"},{"issue":"22","key":"361_CR6","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.3390\/ijms21228421","volume":"21","author":"C Marogianni","year":"2020","unstructured":"Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and inflammation-an interesting interplay in Parkinson\u2019s disease. Int J Mol Sci. 2020;21(22):8421.","journal-title":"Int J Mol Sci"},{"issue":"Pt B","key":"361_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","volume":"109","author":"EM Rocha","year":"2018","unstructured":"Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease. Neurobiol Dis. 2018;109(Pt B):249\u201357.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"361_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/j.1471-4159.2007.05087.x","volume":"104","author":"AD Reynolds","year":"2008","unstructured":"Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson\u2019s disease. J Neurochem. 2008;104(6):1504\u201325.","journal-title":"J Neurochem"},{"issue":"2","key":"361_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neulet.2012.06.070","volume":"523","author":"DK Stone","year":"2012","unstructured":"Stone DK, Kiyota T, Mosley RL, Gendelman HE. A model of nitric oxide induced alpha-synuclein misfolding in Parkinson\u2019s disease. Neurosci Lett. 2012;523(2):167\u201373.","journal-title":"Neurosci Lett"},{"issue":"12","key":"361_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.molmed.2011.08.005","volume":"17","author":"HE Gendelman","year":"2011","unstructured":"Gendelman HE, Appel SH. Neuroprotective activities of regulatory T cells. Trends Mol Med. 2011;17(12):687\u20138.","journal-title":"Trends Mol Med"},{"key":"361_CR11","doi-asserted-by":"publisher","first-page":"120786","DOI":"10.1016\/j.biomaterials.2021.120786","volume":"272","author":"KE Olson","year":"2021","unstructured":"Olson KE, Namminga KL, Lu Y, Thurston MJ, Schwab AD, de Picciotto S, et al. Granulocyte-macrophage colony-stimulating factor mRNA and neuroprotective immunity in Parkinson\u2019s disease. Biomaterials. 2021;272:120786.","journal-title":"Biomaterials"},{"issue":"9","key":"361_CR12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1089\/ars.2009.2460","volume":"11","author":"DK Stone","year":"2009","unstructured":"Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson\u2019s disease. Antioxid Redox Signal. 2009;11(9):2151\u201366.","journal-title":"Antioxid Redox Signal"},{"issue":"s1","key":"361_CR13","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.3233\/JPD-223278","volume":"12","author":"M Saleh","year":"2022","unstructured":"Saleh M, Markovic M, Olson KE, Gendelman HE, Mosley RL. Therapeutic strategies for immune transformation in Parkinson\u2019s disease. J Parkinsons Dis. 2022;12(s1):S201\u201322.","journal-title":"J Parkinsons Dis"},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jconrel.2022.06.024","volume":"348","author":"P Yeapuri","year":"2022","unstructured":"Yeapuri P, Olson KE, Lu Y, Abdelmoaty MM, Namminga KL, Markovic M, et al. Development of an extended half-life GM-CSF fusion protein for Parkinson\u2019s disease. J Control Release. 2022;348:951\u201365.","journal-title":"J Control Release"},{"key":"361_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fncel.2019.00421","volume":"13","author":"RL Mosley","year":"2019","unstructured":"Mosley RL, Lu Y, Olson KE, Machhi J, Yan W, Namminga KL, et al. A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson\u2019s disease. Front Cell Neurosci. 2019;13:421.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"361_CR16","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.0901852","volume":"184","author":"AD Reynolds","year":"2010","unstructured":"Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson\u2019s disease. J Immunol. 2010;184(5):2261\u201371.","journal-title":"J Immunol"},{"issue":"4","key":"361_CR17","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s13311-020-00877-8","volume":"17","author":"KE Olson","year":"2020","unstructured":"Olson KE, Namminga KL, Schwab AD, Thurston MJ, Lu Y, Woods A, et al. Neuroprotective activities of long-acting granulocyte-macrophage colony-stimulating factor (mPDM608) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neurotherapeutics. 2020;17(4):1861\u201377.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"361_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1189\/jlb.0507296","volume":"82","author":"AD Reynolds","year":"2007","unstructured":"Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson\u2019s disease. J Leukoc Biol. 2007;82(5):1083\u201394.","journal-title":"J Leukoc Biol"},{"key":"361_CR19","doi-asserted-by":"publisher","first-page":"706186","DOI":"10.3389\/fimmu.2021.706186","volume":"12","author":"HM Lazarus","year":"2021","unstructured":"Lazarus HM, Ragsdale CE, Gale RP, Lyman GH. Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? Front Immunol. 2021;12:706186.","journal-title":"Front Immunol"},{"issue":"1","key":"361_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13024-018-0255-7","volume":"13","author":"CR Schutt","year":"2018","unstructured":"Schutt CR, Gendelman HE, Mosley RL. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson\u2019s disease. Mol Neurodegener. 2018;13(1):26.","journal-title":"Mol Neurodegener"},{"issue":"1\u20132","key":"361_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.10.009","volume":"265","author":"LM Kosloski","year":"2013","unstructured":"Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol. 2013;265(1\u20132):1\u201310.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"361_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1460-9568.2009.06653.x","volume":"29","author":"NK Kim","year":"2009","unstructured":"Kim NK, Choi BH, Huang X, Snyder BJ, Bukhari S, Kong TH, et al. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson\u2019s disease model. Eur J Neurosci. 2009;29(5):891\u2013900.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"361_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/brb3.11","volume":"1","author":"ME Choudhury","year":"2011","unstructured":"Choudhury ME, Sugimoto K, Kubo M, Nagai M, Nomoto M, Takahashi H, et al. A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats. Brain Behav. 2011;1(1):26\u201343.","journal-title":"Brain Behav"},{"issue":"1","key":"361_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2011.02.011","volume":"43","author":"EN Mangano","year":"2011","unstructured":"Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson\u2019s disease. Neurobiol Dis. 2011;43(1):99\u2013112.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"361_CR25","doi-asserted-by":"crossref","first-page":"e12158","DOI":"10.1002\/trc2.12158","volume":"7","author":"H Potter","year":"2021","unstructured":"Potter H, Woodcock JH, Boyd TD, Coughlan CM, O\u2019Shaughnessy JR, Borges MT, et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7(1):e12158.","journal-title":"Alzheimers Dement (N Y)"},{"key":"361_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"HE Gendelman","year":"2017","unstructured":"Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. NPJ Parkinsons Dis. 2017;3:10.","journal-title":"NPJ Parkinsons Dis"},{"issue":"21","key":"361_CR27","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa041109","volume":"352","author":"JR Korzenik","year":"2005","unstructured":"Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn\u2019s Disease Study G. Sargramostim for active Crohn\u2019s disease. N Engl J Med. 2005;352(21):2193\u2013201.","journal-title":"N Engl J Med"},{"key":"361_CR28","doi-asserted-by":"publisher","first-page":"103380","DOI":"10.1016\/j.ebiom.2021.103380","volume":"67","author":"KE Olson","year":"2021","unstructured":"Olson KE, Namminga KL, Lu Y, Schwab AD, Thurston MJ, Abdelmoaty MM, et al. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson\u2019s disease. EBioMedicine. 2021;67:103380.","journal-title":"EBioMedicine"},{"key":"361_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usac362","author":"R Paine","year":"2022","unstructured":"Paine R, Chasse R, Halstead ES, Nfonoyim J, Park DJ, Byun T, et al. Inhaled sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor) for COVID-19-associated acute hypoxemia: results of the phase 2, randomized, open-label trial (iLeukPulm). Mil Med. 2022. https:\/\/doi.org\/10.1093\/milmed\/usac362.","journal-title":"Mil Med"},{"key":"361_CR30","first-page":"CD008538","volume":"11","author":"L Roth","year":"2011","unstructured":"Roth L, Macdonald JK, McDonald JW, Chande N. Sargramostim (GM-CSF) for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2011;11:CD008538.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"361_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1358\/dot.2018.54.11.2899370","volume":"54","author":"VK Singh","year":"2018","unstructured":"Singh VK, Seed TM. An update on sargramostim for treatment of acute radiation syndrome. Drugs Today (Barc). 2018;54(11):679\u201393.","journal-title":"Drugs Today (Barc)"},{"issue":"17","key":"361_CR32","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2014.13943","volume":"312","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;312(17):1744\u201353.","journal-title":"JAMA"},{"issue":"7","key":"361_CR33","doi-asserted-by":"publisher","first-page":"e958","DOI":"10.1002\/ctm2.958","volume":"12","author":"MM Abdelmoaty","year":"2022","unstructured":"Abdelmoaty MM, Machhi J, Yeapuri P, Shahjin F, Kumar V, Olson KE, et al. Monocyte biomarkers define sargramostim treatment outcomes for Parkinson\u2019s disease. Clin Transl Med. 2022;12(7):e958.","journal-title":"Clin Transl Med"},{"issue":"8","key":"361_CR34","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"X Hou","year":"2020","unstructured":"Hou X, Watzlawik JO, Fiesel FC, Springer W. Autophagy in Parkinson\u2019s disease. J Mol Biol. 2020;432(8):2651\u201372.","journal-title":"J Mol Biol"},{"issue":"4","key":"361_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J Neuroimmune Pharmacol. 2012;7(4):927\u201338.","journal-title":"J Neuroimmune Pharmacol"},{"key":"361_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93:491\u2013507.","journal-title":"Biometrika"},{"issue":"27","key":"361_CR37","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009\u201313.","journal-title":"J Biol Chem"},{"issue":"4","key":"361_CR38","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3892\/mmr.2016.5662","volume":"14","author":"E Xue","year":"2016","unstructured":"Xue E, Zhang Y, Song B, Xiao J, Shi Z. Effect of autophagy induced by dexamethasone on senescence in chondrocytes. Mol Med Rep. 2016;14(4):3037\u201344.","journal-title":"Mol Med Rep"},{"issue":"2","key":"361_CR39","doi-asserted-by":"publisher","first-page":"e187800","DOI":"10.1001\/jamanetworkopen.2018.7800","volume":"2","author":"CA Artusi","year":"2019","unstructured":"Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(2):e187800.","journal-title":"JAMA Netw Open"},{"key":"361_CR40","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fneur.2019.01143","volume":"10","author":"E Palasz","year":"2019","unstructured":"Palasz E, Niewiadomski W, Gasiorowska A, Wysocka A, Stepniewska A, Niewiadomska G. Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson\u2019s disease. Front Neurol. 2019;10:1143.","journal-title":"Front Neurol"},{"issue":"6","key":"361_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.24918","volume":"27","author":"RN Alcalay","year":"2012","unstructured":"Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson\u2019s disease. Mov Disord. 2012;27(6):771\u20134.","journal-title":"Mov Disord"},{"key":"361_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnagi.2014.00036","volume":"6","author":"SE Seidl","year":"2014","unstructured":"Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson\u2019s disease. Front Aging Neurosci. 2014;6:36.","journal-title":"Front Aging Neurosci"},{"key":"361_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","volume":"122","author":"AP Robinson","year":"2014","unstructured":"Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol. 2014;122:173\u201389.","journal-title":"Handb Clin Neurol"},{"key":"361_CR44","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3389\/fimmu.2018.01213","volume":"9","author":"TJ Oberstein","year":"2018","unstructured":"Oberstein TJ, Taha L, Spitzer P, Hellstern J, Herrmann M, Kornhuber J, et al. Imbalance of circulating Th17 and regulatory T cells in Alzheimer\u2019s disease: a case control study. Front Immunol. 2018;9:1213.","journal-title":"Front Immunol"},{"key":"361_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fnagi.2019.00124","volume":"11","author":"L Sun","year":"2019","unstructured":"Sun L, Ju T, Wang T, Zhang L, Ding F, Zhang Y, et al. Decreased Netrin-1 and correlated Th17\/Tregs balance disorder in Abeta1-42 induced Alzheimer\u2019s disease model rats. Front Aging Neurosci. 2019;11:124.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"361_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12974-019-1550-0","volume":"16","author":"TJ Kramer","year":"2019","unstructured":"Kramer TJ, Hack N, Bruhl TJ, Menzel L, Hummel R, Griemert EV, et al. Depletion of regulatory T cells increases T cell brain infiltration, reactive astrogliosis, and interferon-gamma gene expression in acute experimental traumatic brain injury. J Neuroinflammation. 2019;16(1):163.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"361_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12975-016-0465-7","volume":"7","author":"A Liesz","year":"2016","unstructured":"Liesz A, Kleinschnitz C. Regulatory T cells in post-stroke immune homeostasis. Transl Stroke Res. 2016;7(4):313\u201321.","journal-title":"Transl Stroke Res"},{"issue":"4","key":"361_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JPD-130250","volume":"3","author":"GT Kannarkat","year":"2013","unstructured":"Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson\u2019s disease. J Parkinsons Dis. 2013;3(4):493\u2013514.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"361_CR49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nn.4528","volume":"20","author":"Y Dombrowski","year":"2017","unstructured":"Dombrowski Y, O\u2019Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20(5):674\u201380.","journal-title":"Nat Neurosci"},{"key":"361_CR50","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.nbd.2020.104868","volume":"140","author":"LL McIntyre","year":"2020","unstructured":"McIntyre LL, Greilach SA, Othy S, Sears-Kraxberger I, Wi B, Ayala-Angulo J, et al. Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. Neurobiol Dis. 2020;140:104868.","journal-title":"Neurobiol Dis"},{"key":"361_CR51","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fnins.2019.01107","volume":"13","author":"SS Duffy","year":"2019","unstructured":"Duffy SS, Keating BA, Moalem-Taylor G. Adoptive transfer of regulatory T cells as a promising immunotherapy for the treatment of multiple sclerosis. Front Neurosci. 2019;13:1107.","journal-title":"Front Neurosci"},{"key":"361_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.intimp.2018.06.015","volume":"61","author":"P Shi","year":"2018","unstructured":"Shi P, Qu H, Nian D, Chen Y, Liu X, Li Q, et al. Treatment of Guillain-Barre syndrome with Bifidobacterium infantis through regulation of T helper cells subsets. Int Immunopharmacol. 2018;61:290\u20136.","journal-title":"Int Immunopharmacol"},{"issue":"2\u20133","key":"361_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12026-014-8580-6","volume":"60","author":"MS Maddur","year":"2014","unstructured":"Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1\/Th17 cells and regulatory T cells in Guillain\u2013Barre syndrome patients. Immunol Res. 2014;60(2\u20133):320\u20139.","journal-title":"Immunol Res"},{"issue":"2","key":"361_CR54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11481-019-09888-5","volume":"15","author":"Y Huang","year":"2020","unstructured":"Huang Y, Liu Z, Cao BB, Qiu YH, Peng YP. Treg cells attenuate neuroinflammation and protect neurons in a mouse model of Parkinson\u2019s disease. J Neuroimmune Pharmacol. 2020;15(2):224\u201337.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"Pt 4","key":"361_CR55","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/brain\/awv408","volume":"139","author":"C Dansokho","year":"2016","unstructured":"Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139(Pt 4):1237\u201351.","journal-title":"Brain"},{"issue":"43","key":"361_CR56","doi-asserted-by":"publisher","first-page":"69347","DOI":"10.18632\/oncotarget.12469","volume":"7","author":"H Baek","year":"2016","unstructured":"Baek H, Ye M, Kang GH, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer\u2019s disease model. Oncotarget. 2016;7(43):69347\u201357.","journal-title":"Oncotarget"},{"issue":"4","key":"361_CR57","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1212\/NXI.0000000000000465","volume":"5","author":"JR Thonhoff","year":"2018","unstructured":"Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7738","key":"361_CR58","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-018-0824-5","volume":"565","author":"M Ito","year":"2019","unstructured":"Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565(7738):246\u201350.","journal-title":"Nature"},{"key":"361_CR59","doi-asserted-by":"publisher","first-page":"750542","DOI":"10.3389\/fimmu.2021.750542","volume":"12","author":"P Grover","year":"2021","unstructured":"Grover P, Goel PN, Greene MI. Regulatory T cells: regulation of identity and function. Front Immunol. 2021;12:750542.","journal-title":"Front Immunol"},{"key":"361_CR60","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2013.00152","volume":"4","author":"EG Schmitt","year":"2013","unstructured":"Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol. 2013;4:152.","journal-title":"Front Immunol"},{"key":"361_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.imlet.2022.06.005","volume":"248","author":"A Liston","year":"2022","unstructured":"Liston A, Dooley J, Yshii L. Brain-resident regulatory T cells and their role in health and disease. Immunol Lett. 2022;248:26\u201330.","journal-title":"Immunol Lett"},{"issue":"8","key":"361_CR62","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41588-020-0669-3","volume":"52","author":"EA Bruford","year":"2020","unstructured":"Bruford EA, Braschi B, Denny P, Jones TEM, Seal RL, Tweedie S. Guidelines for human gene nomenclature. Nat Genet. 2020;52(8):754\u20138.","journal-title":"Nat Genet"},{"key":"361_CR63","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.nbd.2020.104760","volume":"137","author":"AD Schwab","year":"2020","unstructured":"Schwab AD, Thurston MJ, Machhi J, Olson KE, Namminga KL, Gendelman HE, et al. Immunotherapy for Parkinson\u2019s disease. Neurobiol Dis. 2020;137:104760.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"361_CR64","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728\u201341.","journal-title":"Cell"},{"key":"361_CR65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fcell.2018.00128","volume":"6","author":"NM Kocaturk","year":"2018","unstructured":"Kocaturk NM, Gozuacik D. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol. 2018;6:128.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"361_CR66","first-page":"25","volume":"12","author":"P Anglade","year":"1997","unstructured":"Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson\u2019s disease. Histol Histopathol. 1997;12(1):25\u201331.","journal-title":"Histol Histopathol"},{"issue":"5","key":"361_CR67","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1161\/01.CIR.0000074209.17561.99","volume":"108","author":"IR Buschmann","year":"2003","unstructured":"Buschmann IR, Busch HJ, Mies G, Hossmann KA. Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor. Circulation. 2003;108(5):610\u20135.","journal-title":"Circulation"},{"issue":"1","key":"361_CR68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.brainres.2006.03.059","volume":"1089","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa T, Suga S, Kawase T, Toda M. Intracarotid injection of granulocyte-macrophage colony-stimulating factor induces neuroprotection in a rat transient middle cerebral artery occlusion model. Brain Res. 2006;1089(1):179\u201385.","journal-title":"Brain Res"},{"issue":"4","key":"361_CR69","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/01.STR.0000259707.43496.71","volume":"38","author":"UC Schneider","year":"2007","unstructured":"Schneider UC, Schilling L, Schroeck H, Nebe CT, Vajkoczy P, Woitzik J. Granulocyte-macrophage colony-stimulating factor-induced vessel growth restores cerebral blood supply after bilateral carotid artery occlusion. Stroke. 2007;38(4):1320\u20138.","journal-title":"Stroke"},{"issue":"1","key":"361_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ejn.13105","volume":"43","author":"JK Theoret","year":"2016","unstructured":"Theoret JK, Jadavji NM, Zhang M, Smith PD. Granulocyte macrophage colony-stimulating factor treatment results in recovery of motor function after white matter damage in mice. Eur J Neurosci. 2016;43(1):17\u201324.","journal-title":"Eur J Neurosci"},{"issue":"10","key":"361_CR71","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1089\/neu.2013.3106","volume":"31","author":"SR Shultz","year":"2014","unstructured":"Shultz SR, Tan XL, Wright DK, Liu SJ, Semple BD, Johnston L, et al. Granulocyte-macrophage colony-stimulating factor is neuroprotective in experimental traumatic brain injury. J Neurotrauma. 2014;31(10):976\u201383.","journal-title":"J Neurotrauma"},{"key":"361_CR72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jneuroim.2014.11.002","volume":"278","author":"ML Kelso","year":"2015","unstructured":"Kelso ML, Elliott BR, Haverland NA, Mosley RL, Gendelman HE. Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma. J Neuroimmunol. 2015;278:162\u201373.","journal-title":"J Neuroimmunol"},{"key":"361_CR73","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jneuroim.2018.03.009","volume":"319","author":"T Kiyota","year":"2018","unstructured":"Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Yokoyama I, et al. Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer\u2019s disease mice. J Neuroimmunol. 2018;319:80\u201392.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"361_CR74","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/j.1471-4159.2009.06432.x","volume":"111","author":"PH Reddy","year":"2009","unstructured":"Reddy PH, Manczak M, Zhao W, Nakamura K, Bebbington C, Yarranton G, et al. Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer\u2019s disease and multiple sclerosis. J Neurochem. 2009;111(6):1514\u201328.","journal-title":"J Neurochem"},{"issue":"1","key":"361_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroscience.2009.05.071","volume":"163","author":"J Sanchez-Ramos","year":"2009","unstructured":"Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer\u2019s mice. Neuroscience. 2009;163(1):55\u201372.","journal-title":"Neuroscience"},{"issue":"Pt 11","key":"361_CR76","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/brain\/120.11.2083","volume":"120","author":"RN McLay","year":"1997","unstructured":"McLay RN, Kimura M, Banks WA, Kastin AJ. Granulocyte-macrophage colony-stimulating factor crosses the blood\u2013brain and blood\u2013spinal cord barriers. Brain. 1997;120(Pt 11):2083\u201391.","journal-title":"Brain"},{"issue":"16","key":"361_CR77","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1097\/00001756-199711100-00033","volume":"8","author":"M Bianchi","year":"1997","unstructured":"Bianchi M, Clavenna A, Bondiolotti GP, Ferrario P, Panerai AE. GM-CSF affects hypothalamic neurotransmitter levels in mice: involvement of interleukin-1. NeuroReport. 1997;8(16):3587\u201390.","journal-title":"NeuroReport"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-023-00361-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T14:19:27Z","timestamp":1702477167000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-023-00361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s40035-023-00361-1","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"5 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by UNMC Institutional Review Board and all subjects signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}